Irbesartan E Idroclorotiazide Tecnigen (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to control elevated blood pressure.

• Hypertension: lowers systolic and diastolic pressure in patients with primary or secondary hypertension.
• Resistant hypertension: provides additional blood‑pressure reduction when monotherapy is insufficient.
• Hypertensive renal disease: helps control pressure while reducing fluid overload.

• Irbesartan selectively blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion, which together reduce vascular resistance and circulating blood volume, resulting in lowered blood pressure.

Common Side Effects

• Dizziness: mild to moderate light‑headedness, especially after the first dose.
• Headache: transient tension‑type headaches.
• Fatigue: general tiredness that often improves with continued therapy.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: mild reductions in potassium or sodium levels.
• Gastrointestinal discomfort: occasional nausea or abdominal cramping.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Acute kidney injury: sudden rise in serum creatinine.
• Significant hypotension: marked drop in blood pressure causing faintness.
• Hyperkalemia: elevated potassium levels, especially when combined with potassium‑sparing agents.
• Pancreatitis: rare inflammation of the pancreas.
• Liver dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, assess baseline blood pressure, renal function, and electrolyte status.

• Monitor blood pressure: adjust dose based on response.
• Check renal function: periodic serum creatinine and eGFR measurements.
• Assess electrolytes: especially potassium and sodium levels.
• Use caution in elderly patients: increased sensitivity to hypotension.
• Avoid in severe hepatic impairment: limited data on safety.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines that affect blood pressure, renal function, or electrolyte balance.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: risk of hyperkalemia.
• ACE inhibitors or aliskiren: additive renal effects.
• NSAIDs: may blunt antihypertensive response and affect kidney function.
• Lithium: increased lithium levels and toxicity.
• High‑dose potassium supplements: risk of severe hyperkalemia.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance hypotensive effect.
• Calcium channel blockers: additive blood‑pressure lowering.
• Antidiabetic agents: may require dose adjustment due to improved glycemic control.
• Antihistamines: possible increase in diuretic‑related dehydration.
• Rifampin: may reduce plasma concentrations of irbesartan.